Oxford BioTherapeutics And Boehringer Ingelheim Enter Collaboration To Discover Novel Antibody Targets In Cancer

Oxford BioTherapeutics (OBT) and Boehringer Ingelheim(BI) have announced a new alliance focused on the discovery of novel cancer antibody targets that OBT will identify with the help of its OGAP(R) discovery platform. Under the collaboration OBT will validate certain targets it has discovered that are compatible with targeting by various antibody drug formats across a range of cancer indications. Following completion of these activities, BI will have the exclusive right to develop and commercialize antibody products for selected programs... via Health News from Medical News Today Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2013/05/oxford-biotherapeutics-and-boehringer.html